{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:19:31Z","timestamp":1790047171121,"version":"4.0.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Considering the lack of evidence, we evaluated the impact on cardiovascular outcome of the systematic introduction in our institution of a personalized strike early and strong (SES) approach for lipid-lowering therapy (LLT) in patients admitted for acute myocardial infarction (MI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We retrospectively analysed data from 500 consecutive patients hospitalized across three periods: Period A (N\u00a0=\u00a0198, January\u2013June 2019), when the low-density lipoprotein cholesterol (LDL-C) goal was &amp;lt;70\u00a0mg\/dL and a stepwise LLT approach was recommended; Period B (N\u00a0=\u00a0180, January\u2013June 2021), when the LDL-C goal was &amp;lt;55\u00a0mg\/dL and a stepwise approach was recommended; Period C (N\u00a0=\u00a0122, January\u2013June 2023), when the LDL-C goal was &amp;lt;55\u00a0mg\/dL and our SES protocol was implemented. Primary endpoints were achievement of the LDL-C goal during follow-up and 1-year incidence of major adverse cardiovascular events (MACE). Compared to the other periods, in Period C, there was a higher use of potent statins, alone or in combination with ezetimibe, and of proprotein convertase subtilisin\/kexin type 9 inhibitor inhibitors at discharge. This translated into higher achievement of the LDL-C goal (83%\u00a0vs. 55% in Period A and 43% in Period B; P\u00a0&amp;lt;\u00a00.001) and reduced incidence of MACE (3%\u00a0vs. 12% and 11%; P\u00a0=\u00a00.026). MACE rates were lowest in patients with early and sustained LDL-C &amp;lt;55\u00a0mg\/dL and in those achieving both LDL-C &amp;lt;55\u00a0mg\/dL and\u00a0\u226550% LDL-C reduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The systematic introduction of a personalized, SES strategy for LLT in patients with acute MI led to greater achievement of LDL-C goal and lower risk of MACE at 1 year vs. the stepwise approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf004","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T01:05:21Z","timestamp":1737767121000},"page":"143-154","source":"Crossref","is-referenced-by-count":22,"title":["Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-3968","authenticated-orcid":false,"given":"Giuseppe","family":"Patti","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, 28100 Novara ,","place":["Italy"]},{"name":"Division of Cardiology, Maggiore della Carit\u00e0 Hospital , Corso Mazzini 18, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-4016","authenticated-orcid":false,"given":"Luca","family":"Cumitini","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Bosco","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marengo","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-8330","authenticated-orcid":false,"given":"Domenico","family":"D'Amario","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, 28100 Novara ,","place":["Italy"]},{"name":"Division of Cardiology, Maggiore della Carit\u00e0 Hospital , Corso Mazzini 18, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-8787","authenticated-orcid":false,"given":"Marco","family":"Mennuni","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, 28100 Novara ,","place":["Italy"]},{"name":"Division of Cardiology, Maggiore della Carit\u00e0 Hospital , Corso Mazzini 18, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Solli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Maggiore della Carit\u00e0 Hospital , Corso Mazzini 18, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-9907","authenticated-orcid":false,"given":"Leonardo","family":"Grisafi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Maggiore della Carit\u00e0 Hospital , Corso Mazzini 18, 28100 Novara ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2025031314294180600_bib1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2025031314294180600_bib2","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2025031314294180600_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"2025031314294180600_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025031314294180600_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025031314294180600_bib6","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"The Lancet"},{"key":"2025031314294180600_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/ehjcvp\/pvac049","article-title":"Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials","volume":"9","author":"Patti","year":"2023","journal-title":"European Heart Journal\u2014Cardiovascular Pharmacotherapy"},{"key":"2025031314294180600_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025031314294180600_bib9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2025031314294180600_bib10","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"The Lancet Regional Health\u2014Europe"},{"key":"2025031314294180600_bib11","doi-asserted-by":"crossref","first-page":"131659","DOI":"10.1016\/j.ijcard.2023.131659","article-title":"Achievement of target LDL-cholesterol level in patients with acute coronary syndrome undergoing percutaneous coronary intervention: the JET-LDL registry","volume":"397","author":"Ferlini","year":"2024","journal-title":"Int J Cardiol"},{"key":"2025031314294180600_bib12","doi-asserted-by":"crossref","first-page":"107141","DOI":"10.1016\/j.vph.2023.107141","article-title":"The effect of the 2019 ESC\/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS EuroPath IV project","volume":"148","author":"Laufs","year":"2023","journal-title":"Vasc Pharmacol"},{"key":"2025031314294180600_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"2025031314294180600_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MCA.0000000000001420","article-title":"Lipid-lowering therapy after acute coronary syndromes: a multinational European survey","volume":"36","author":"Tsaban","year":"2025","journal-title":"Coron Artery Dis"},{"key":"2025031314294180600_bib15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2025031314294180600_bib16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025031314294180600_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","article-title":"Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients","volume":"255","author":"Gitt","year":"2016","journal-title":"Atherosclerosis"},{"key":"2025031314294180600_bib18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","article-title":"Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2025031314294180600_bib19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"2025031314294180600_bib20","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.atherosclerosissup.2021.01.009","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS patient pathway project","volume":"42","author":"Landmesser","year":"2020","journal-title":"Atheroscler Suppl"},{"key":"2025031314294180600_bib21","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025031314294180600_bib22","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","article-title":"Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry","volume":"31","author":"Gargiulo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025031314294180600_bib23","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"key":"2025031314294180600_bib24","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3390\/jcm13072043","article-title":"Lipid-lowering therapy after acute coronary syndrome","volume":"13","author":"Pogran","year":"2024","journal-title":"J Clin Med"},{"key":"2025031314294180600_bib25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jacc.2007.02.025","article-title":"Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial","volume":"49","author":"Patti","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2025031314294180600_bib26","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2025031314294180600_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jacc.2016.10.029","article-title":"Intracoronary imaging, cholesterol efflux, and transcriptomes after intensive statin treatment: the YELLOW II study","volume":"69","author":"Kini","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025031314294180600_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jjcc.2019.08.002","article-title":"Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome","volume":"75","author":"Yano","year":"2020","journal-title":"J Cardiol"},{"key":"2025031314294180600_bib29","first-page":"1308","article-title":"Effect of Evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC: Cardiovasc Imaging"},{"key":"2025031314294180600_bib30","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2025031314294180600_bib31","first-page":"260","article-title":"Effects of lipid lowering therapies on vulnerable plaque features: an updated narrative review of the literature","volume":"10","author":"Biccir\u00e8","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2025031314294180600_bib32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijcard.2011.01.071","article-title":"Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients","volume":"158","author":"Egede","year":"2012","journal-title":"Int J Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf004\/61622867\/pvaf004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/2\/143\/61622867\/pvaf004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/2\/143\/61622867\/pvaf004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T14:30:18Z","timestamp":1741876218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/2\/143\/7979010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,24]]},"published-print":{"date-parts":[[2025,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf004","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,24]]}}}